Sector: Healthcare | Industry: Biotechnology & Medical Research |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 409 ILLINOIS STREET SAN FRANCISCO CA 94158 |
Tel: | N/A |
Website: | https://www.fibrogen.com |
IR: | See website |
Key People | ||
Thane Wettig Chief Executive Officer, Director, Chief Commercial Officer | Juan Graham Chief Financial Officer | Deyaa Adib Senior Vice President and Chief Medical Officer | Christine L. Chung Senior Vice President, China Operations |
Business Overview |
FibroGen, Inc. is a biopharmaceutical company. The Company is engaged in developing and commercializing a diversified pipeline of novel therapeutics that work at the frontiers of cancer biology and anemia. Its clinical, commercial, and research programs include Pamrevlumab, which is a first-in-class antibody being developed by FibroGen to inhibit the activity of connective tissue growth factor (CTGF). Pamrevlumab is in Phase III clinical development for the treatment of locally advanced unresectable pancreatic cancer (LAPC) and in Phase 2/3 for the treatment of metastatic pancreatic cancer and Roxadustat, an oral medication, is the first in a new class of medicines comprising HIF-PH inhibitors that promote erythropoiesis, or red blood cell production, through increased endogenous production of erythropoietin, improved iron absorption and mobilization, and downregulation of hepcidin. It also develops FG-3165: Anti-Gal9 Antibody and FG-3175: Anti-CCR8 Antibody. |
Financial Overview |
For the three months ended 31 March 2024, FibroGen Inc revenues increased 55% to $55.9M. Net loss decreased 57% to $32.9M. Revenues reflect Drug product revenue increase from $2.1M to $24.5M, Product revenue increase of 26% to $30.5M. Lower net loss reflects Research and Development decrease of 48% to $38.4M (expense), General and Administrative decrease of 33% to $22.8M (expense). |
Employees: | 486 as of Dec 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $28.29M as of Mar 31, 2024 |
Annual revenue (TTM): | $167.49M as of Mar 31, 2024 |
EBITDA (TTM): | -$216.40M as of Mar 31, 2024 |
Net annual income (TTM): | -$240.46M as of Mar 31, 2024 |
Free cash flow (TTM): | -$274.68M as of Mar 31, 2024 |
Net Debt Last Fiscal Year: | N/A |
Shares outstanding: | 99,475,398 as of Apr 30, 2024 |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |